Hansoh Pharmaceutical Group Company Limited reported no changes in either authorised or issued share capital for the month ended 31 March 2026. Authorised capital remained at 20.00 billion ordinary shares with a par value of HKD 0.00001, equivalent to HKD 0.20 million.

Issued share capital also held steady at 6.06 billion shares, and the company continued to hold no treasury shares. The board confirmed that public float requirements were satisfied, with at least 16.21 % of the share class in public hands.

Outstanding zero-coupon convertible bonds due 2033 totaled HKD 4.68 billion at month-end. If fully converted at the set price of HKD 57.39 per share, these bonds could generate up to 81.55 million new ordinary shares—representing roughly 1.35 % of the current issued share base.

No activity was recorded under share option schemes, warrants, other convertible instruments, or any additional equity agreements during the period. Ms. Zhong Shengli, Joint Company Secretary, submitted the monthly return on 2 April 2026.